Skip to main content
Log in

Cost-of-Illness Studies

A Review of Current Methods

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The number of cost-of-illness (COI) studies has expanded considerably over time. One outcome of this growth is that the reported COI estimates are inconsistent across studies, thereby raising concerns over the validity of the estimates and methods. Several factors have been identified in the literature as reasons for the observed variation in COI estimates. To date, the variation in the methods used to calculate costs has not been examined in great detail even though the variations in methods are a major driver of variation in COI estimates. The objective of this review was to document the variation in the methodologies employed in COI studies and to highlight the benefits and limitations of these methods.

The review of COI studies was implemented following a four-step procedure: (i) a structured literature search of MEDLINE, JSTOR and EconLit; (ii) a review of abstracts using pre-defined inclusion and exclusion criteria; (iii) a full-text review using pre-defined inclusion and exclusion criteria; and (iv) classification of articles according to the methods used to calculate costs. This review identified four COI estimation methods (Sum_All Medical, Sum_Diagnosis Specific, Matched Control and Regression) that were used in categorising articles. Also, six components of direct medical costs and five components of indirect/non-medical costs were identified and used in categorising articles.

365 full-length articles were reflected in the current review following the structured literature search. The top five cost components were emergency room/inpatient hospital costs, outpatient physician costs, drug costs, productivity losses and laboratory costs. The dominant method, Sum_Diagnosis Specific, was a total costing approach that restricted the summation of medical expenditures to those related to a diagnosis of the disease of interest.

There was considerable variation in the methods used within disease subcategories. In several disease subcategories (e.g. asthma, dementia, diabetes mellitus), all four estimation methods were represented, and in other cases (e.g. HIV/AIDS, obesity, stroke, urinary incontinence, schizophrenia), three of the four estimation methods were represented. There was also evidence to suggest that the strengths and weaknesses of each method were considered when applying a method to a specific illness. Comparisons and assessments of COI estimates should consider the method used to estimate costs both as an important source of variation in the reported COI estimates and as a marker of the reliability of the COI estimate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001; 19 (2): 207–213

    Article  PubMed  CAS  Google Scholar 

  2. Shaya FT, Mullins CD, Wong W. Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2 (5): 435–442

    Article  Google Scholar 

  3. Mittendorf T, Merkesdal S, Huelsemann JL, et al. Implementing standardized cost categories within economic evaluations in musculoskeletal diseases. Eur J Health Econ 2003; 4 (1): 43–49

    Article  PubMed  CAS  Google Scholar 

  4. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–462

    Article  PubMed  CAS  Google Scholar 

  5. Rice DP. Estimating the costs of illness. Health Economics Series No. 6. DHEW Publication No. (PHS)947-6. Rockville (MD): U.S. Department of Health, Education and Welfare, 1966

    Google Scholar 

  6. Cooper BS, Rice DP. The economic costs of illness revisited. Soc Secur Bull 1976; 39 (2): 21–36

    PubMed  CAS  Google Scholar 

  7. Berk A, Paringer L, Mushkin SJ. The economic costs of illness: fiscal 1975. Med Care 1978; 26 (9): 785–790

    Article  Google Scholar 

  8. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy 1987; 8: 317–323

    Article  Google Scholar 

  9. DeLeire T, Manning W. Labor market costs of illness: prevalence matters. Health Econ 2004; 13 (3): 239–250

    Article  PubMed  Google Scholar 

  10. Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ 2002; 11 (3): 221–231

    Article  PubMed  Google Scholar 

  11. Koopmanschap MA. Cost-of-illness studies: useful for health policy? Pharmacoeconomics 1998; 14 (2): 143–148

    Article  PubMed  CAS  Google Scholar 

  12. Mooney G, Wiseman V. Burden of disease and priority setting [comment]. Health Econ 2000; 9 (5): 369–372

    Article  PubMed  CAS  Google Scholar 

  13. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  14. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000; 320 (7245): 1335

    Article  PubMed  CAS  Google Scholar 

  15. Kaste M, Fogelholm R, Rissanen A. Economic burden of stroke and the evaluation of new therapies. Public Health 1998; 112 (2): 103–112

    PubMed  CAS  Google Scholar 

  16. Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000; 6: 693–7000

    PubMed  CAS  Google Scholar 

  17. Norlund A, Apelqvist J, Bitzen PO, et al. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med 2001; 250 (1): 57–65

    Google Scholar 

  18. Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health 2001; 4 (4): 329–334

    PubMed  CAS  Google Scholar 

  19. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998; 39 (7): 776–786

    Article  PubMed  CAS  Google Scholar 

  20. Andersen CK, Andersen K, Kragh-Sorensen P. Cost function estimation: the choice of a model to apply to dementia. Health Econ 2000; 9 (5): 397–409

    Article  PubMed  CAS  Google Scholar 

  21. Leon J, Neumann PJ. The cost of Alzheimer’s disease in managed care: a cross-sectional study. Am J Manag Care 1999; 5 (7): 867–877

    PubMed  CAS  Google Scholar 

  22. Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff 2001; 20 (6): 233–241

    Article  CAS  Google Scholar 

  23. Hodgson TA. Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell, et al. (Health Policy, 8 (1987) 317-323). Health Policy 1989; 11 (1): 57–60

    Article  CAS  Google Scholar 

  24. Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer’s disease: part I. Assessment. Am Fam Physician 2002; 65 (11): 2263–2272

    PubMed  Google Scholar 

  25. Pradalier A, Auray JP, El Hasnaoui A, et al. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study. Pharmacoeconomics 2004; 22 (15): 985–999

    Article  PubMed  Google Scholar 

  26. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53 (10): 1471–1478

    Article  PubMed  CAS  Google Scholar 

  27. Wlodarczyk J, Whyte P, Cockrum P, et al. Pterygium in Australia: a cost of illness study. Clin Exp Ophthalmol 2001; 29 (6): 370–375

    Article  CAS  Google Scholar 

  28. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22 (17): 3524–3530

    Article  PubMed  Google Scholar 

  29. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004; 15 (3): 526–536

    Article  PubMed  CAS  Google Scholar 

  30. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med 2004; 5 (2): 93–98

    Article  PubMed  CAS  Google Scholar 

  31. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004; 63 (4): 395–401

    Article  PubMed  CAS  Google Scholar 

  32. Halpern MT, Schmier JK, Richner R, et al. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma 2004; 41 (1): 117–126

    Article  PubMed  Google Scholar 

  33. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–351

    Article  PubMed  Google Scholar 

  34. van den Brandhof WE, De Wit GA, de Wit MA, et al. Costs of gastroenteritis in The Netherlands. Epidemiol Infect 2004; 132 (2): 211–221

    Article  PubMed  Google Scholar 

  35. Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004; 171 (6 Pt 1): 2250–2254

    Article  PubMed  Google Scholar 

  36. Nsengiyumva G, Druet-Cabanac M, Nzisabira L, et al. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia 2004; 45 (6): 673–677

    Article  PubMed  Google Scholar 

  37. Turner DA, Shaw C, McGrother CW, et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004; 93 (9): 1246–1252

    Article  PubMed  CAS  Google Scholar 

  38. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004; 91 (1): 77–83

    Article  PubMed  CAS  Google Scholar 

  39. Yelin E, Cisternas MG, Pasta DJ, et al. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum 2004; 50 (7): 2317–2326

    Article  PubMed  Google Scholar 

  40. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164 (15): 1653–1661

    Article  PubMed  Google Scholar 

  41. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20 (7): 455–462

    Article  PubMed  Google Scholar 

  42. Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer’s disease: the role of comorbid conditions, disease stage, and pharmacotherapy. Fam Med 2002; 34 (7): 528–535

    PubMed  Google Scholar 

  43. Dawson KG, Gomes D, Gerstein H, et al. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002; 25 (8): 1303–1307

    Article  PubMed  Google Scholar 

  44. Carr VJ, Neil AL, Halpin SA, et al. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003; 37 (1): 31–40

    Article  PubMed  Google Scholar 

  45. Carapetis JR, Russell DM, Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine 2004; 23 (6): 755–761

    Article  PubMed  Google Scholar 

  46. Pirson M, Dramaix M, Struelens M, et al. Costs associated with hospital-acquired bacteraemia in a Belgian hospital. J Hosp Infect 2005; 59 (1): 33–40

    Article  PubMed  CAS  Google Scholar 

  47. Calhoun EA, McNaughton Collins M, Pontari MA, et al. The economic impact of chronic prostatitis. Arch Intern Med 2004; 164 (11): 1231–1236

    Article  PubMed  Google Scholar 

  48. Stothers L, Thom D, Calhoun E. Urologic diseases in America project: urinary incontinence in males: demographics and economic burden. J Urol 2005; 173 (4): 1302–1308

    Article  PubMed  Google Scholar 

  49. Penberthy LT, Towne A, Garnett LK, et al. Estimating the economic burden of status epilepticus to the health care system. Seizure 2005; 14 (1): 46–51

    Article  PubMed  CAS  Google Scholar 

  50. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004; 20 (12): 1929–1936

    Article  PubMed  Google Scholar 

  51. Verstappen SM, Verkleij H, Bijlsma JW, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004; 63 (7): 817–824

    Article  PubMed  CAS  Google Scholar 

  52. Coello R, Charlett A, Wilson J, et al. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005; 60 (2): 93–103

    Article  PubMed  CAS  Google Scholar 

  53. Lanzieri TM, Parise MS, Siqueira MM, et al. Incidence, clinical features and estimated costs of congenital rubella syndrome after a large rubella outbreak in Recife, Brazil, 1999–2000. Pediatr Infect Dis J 2004; 23 (12): 1116–1122

    PubMed  Google Scholar 

  54. Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64 (3): 396–402

    Article  PubMed  CAS  Google Scholar 

  55. Oliva J, Lobo F, Molina B, et al. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004; 27 (11): 2616–2621

    Article  PubMed  Google Scholar 

  56. Wyss K, Hutton G, N’Diekhor Y. Costs attributable to AIDS at household level in Chad. AIDS Care 2004; 16 (7): 808–816

    Article  PubMed  CAS  Google Scholar 

  57. Zohrabian A, Meltzer MI, Ratard R, et al. West Nile virus economic impact, Louisiana, 2002. Emerg Infect Dis 2004; 10 (10): 1736–1744

    Article  PubMed  Google Scholar 

  58. Hallert E, Husberg M, Jonsson D, et al. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology 2004; 43 (11): 1374–1382

    Article  PubMed  CAS  Google Scholar 

  59. Gil A, Carrasco P, Jimenez R, et al. Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999–2000. Vaccine 2004; 22 (17–18): 2221–2225

    Article  PubMed  CAS  Google Scholar 

  60. Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30 (6): 1318–1325

    PubMed  Google Scholar 

  61. O’Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25 (3): 1017–1038

    Article  PubMed  Google Scholar 

  62. Gendo K, Sullivan SD, Lozano P, et al. Resource costs for asthma-related care among pediatric patients in managed care. Ann Allergy Asthma Immunol 2003; 91 (3): 251–257

    Article  PubMed  Google Scholar 

  63. Leigh JP, Yasmeen S, Miller TR. Medical costs of fourteen occupational illnesses in the United States in 1999. Scand J Work Environ Health 2003; 29 (4): 304–313

    Article  PubMed  Google Scholar 

  64. Snowden CB, Miller TR, Jensen AF, et al. Costs of medically treated craniofacial conditions. Public Health Rep 2003; 118 (1): 10–17

    PubMed  Google Scholar 

  65. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S23–S31

    Article  PubMed  Google Scholar 

  66. Halpern MT, Musin A, Sondhi S. Economic analysis of the Confronting COPD survey: methodology. Respir Med 2003; 97 Suppl. C: S15–S22

    Article  Google Scholar 

  67. Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97 Suppl. C: S3–S14

    Article  Google Scholar 

  68. Piperno D, Huchon G, Pribil C, et al. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S33–S42

    Article  Google Scholar 

  69. Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S51–S59

    Article  Google Scholar 

  70. Britton M. The burden of COPD in the UK: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S71–S79

    Article  Google Scholar 

  71. Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S81–S89

    Article  Google Scholar 

  72. Ekman M, Johnell O, Lidgren L. The economic cost of low back pain in Sweden in 2001. Acta Orthop 2005; 76 (2): 275–284

    Article  PubMed  Google Scholar 

  73. Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004; 27 (11): 1034–1039

    PubMed  CAS  Google Scholar 

  74. Soderlin MK, Kautiainen H, Skogh T, et al. Quality of life and economic burden of illness in very early arthritis: a population based study in southern Sweden. J Rheumatol 2004; 31 (9): 1717–1722

    PubMed  Google Scholar 

  75. O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003; 3 (1): 7

    Article  PubMed  Google Scholar 

  76. O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3 (1): 17

    Article  PubMed  Google Scholar 

  77. Birnbaum HG, Leong SA, Oster EF, et al. Cost of stress urinary incontinence: a claims data analysis. Pharmacoeconomics 2004; 22 (2): 95–105

    Article  PubMed  Google Scholar 

  78. Garis RI, Farmer KC. Examining costs of chronic conditions in a Medicaid population. Manag Care 2002; 11 (8): 43–50

    PubMed  Google Scholar 

  79. Verboom P, Hakkaart-Van L, Sturkenboom M, et al. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147 (4): 716–724

    Article  PubMed  CAS  Google Scholar 

  80. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46 (3): 361–370

    Article  PubMed  Google Scholar 

  81. Hemmila HM. Quality of life and cost of care of back pain patients in Finnish general practice. Spine 2002; 27 (6): 647–653

    Article  PubMed  Google Scholar 

  82. Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med 2004; 46 (4): 398–412

    Article  PubMed  Google Scholar 

  83. Andersen CK, Lauridsen J, Andersen K, et al. Cost of dementia: impact of disease progression estimated in longitudinal data. Scand J Public Health 2003; 31 (2): 119–125

    Article  PubMed  Google Scholar 

  84. Tu F, Anan M, Kiyohara Y, et al. Analysis of hospital charges for ischemic stroke in Fukuoka, Japan. Health Policy 2003; 66 (3): 239–246

    Article  PubMed  Google Scholar 

  85. Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/ hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003; 42 (12): 1415–1423

    Article  PubMed  Google Scholar 

  86. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23 (5): 723–729

    Article  PubMed  CAS  Google Scholar 

  87. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64 (12): 1465–1475

    Article  PubMed  Google Scholar 

  88. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004; 83 (1): 25–32

    Article  PubMed  CAS  Google Scholar 

  89. Martin BC, Ganguly R, Pannicker S, et al. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin 2003; 19 (8): 771–780

    Article  PubMed  Google Scholar 

  90. Guillemin F, Durieux S, Daures JP, et al. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004; 31 (7): 1297–1304

    PubMed  Google Scholar 

  91. Dewey HM, Thrift AG, Mihalopoulos C, et al. Lifetime cost of stroke subtypes in Australia: findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003; 34 (10): 2502–2507

    Article  PubMed  Google Scholar 

  92. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis Rheum 2003; 48 (10): 2750–2762

    Article  PubMed  Google Scholar 

  93. Murman DL, Kuo SB, Powell MC, et al. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003; 61 (7): 944–949

    Article  PubMed  Google Scholar 

  94. Herjavecz I, Nagy GB, Gyurkovits K, et al. Cost, morbidity, and control of asthma in Hungary: the Hunair Study. J Asthma 2003; 40 (6): 673–681

    Article  PubMed  Google Scholar 

  95. Sansom SL, Cotter SM, Smith F, et al. Costs of a hepatitis A outbreak affecting homosexual men: Franklin County, Ohio, 1999. Am J Prev Med 2003; 25 (4): 343–346

    Article  PubMed  Google Scholar 

  96. Norlund A, Alvegard T, Lithman T, et al. Prostate cancer: prevalence-based healthcare costs. Scand J Urol Nephrol 2003; 37 (5): 371–375

    Article  PubMed  Google Scholar 

  97. Burge RT, King AB, Balda E, et al. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025. Value Health 2003; 6 (5): 574–583

    Article  PubMed  Google Scholar 

  98. Soderlin MK, Kautiainen H, Jonsson D, et al. The costs of early inflammatory joint disease: a population-based study in southern Sweden. Scand J Rheumatol 2003; 32 (4): 216–224

    Article  PubMed  CAS  Google Scholar 

  99. Boonen A, van der Heijde D, Landewe R, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62 (8): 732–740

    Article  PubMed  CAS  Google Scholar 

  100. Boonen A, van der Heijde D, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient’s perspective. Ann Rheum Dis 2003; 62 (8): 741–747

    Article  PubMed  CAS  Google Scholar 

  101. Stewart S, Murphy N, Walker A, et al. The current cost of angina pectoris to the National Health Service in the UK. Heart 2003; 89 (8): 848–853

    Article  PubMed  CAS  Google Scholar 

  102. Melton III LJ, Gabriel SE, Crowson CS, et al. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003; 14 (5): 383–388

    Article  PubMed  Google Scholar 

  103. Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int 2003; 14 (5): 429–436

    Article  PubMed  Google Scholar 

  104. Rothbard AB, Metraux S, Blank MB. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS. Psychiatr Serv 2003; 54 (9): 1240–1246

    Article  PubMed  Google Scholar 

  105. Jarbrink K, Fombonne E, Knapp M. Measuring the parental, service and cost impacts of children with autistic spectrum disorder: a pilot study. J Autism Dev Disord 2003; 33 (4): 395–402

    Article  PubMed  Google Scholar 

  106. Rigaud AS, Fagnani F, Bayle C, et al. Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol 2003; 16 (3): 140–145

    Article  PubMed  Google Scholar 

  107. Burd L, Klug MG, Coumbe MJ, et al. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol 2003; 18 (8): 555–561

    Article  PubMed  Google Scholar 

  108. Braud AC, Levy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 2003; 21 (9): 671–679

    Article  PubMed  Google Scholar 

  109. Birnbaum H, Morley M, Leong S, et al. Lower respiratory tract infections: impact on the workplace [published erratum appears in Pharmacoeconomics 2003; 21 (12): 883]. Pharmacoeconomics 2003; 21 (10): 749–759

    Article  PubMed  Google Scholar 

  110. Youman P, Wilson K, Harraf F, et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21 Suppl. 1: 43–50

    Article  PubMed  Google Scholar 

  111. Leader S, Yang H, De Vincenzo J, et al. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health 2003; 6 (2): 100–106

    Article  PubMed  Google Scholar 

  112. Bungum T, Satterwhite M, Jackson AW, et al. The relationship of body mass index, medical costs, and job absenteeism. Am J Health Behav 2003; 27 (4): 456–462

    Article  PubMed  Google Scholar 

  113. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183: 514–519

    Article  PubMed  Google Scholar 

  114. Schwenkglenks M, Lowy A, Anderhub H, et al. Costs of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value Health 2003; 6 (1): 75–83

    Article  PubMed  Google Scholar 

  115. Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the top 10 “physical and mental ” health conditions affecting six large US employers in 1999. J Occup Environ Med 2003; 45 (1): 5–14

    Article  PubMed  Google Scholar 

  116. Bonastre J, Le Pen C, Soubrane G, et al. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21 (3): 181–190

    Article  PubMed  Google Scholar 

  117. Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003; 21 (1): 116–122

    Article  PubMed  CAS  Google Scholar 

  118. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003; 49 (1): 64–70

    Article  PubMed  Google Scholar 

  119. Perencevich EN, Sands KE, Cosgrove SE, et al. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003; 9 (2): 196–203

    Article  PubMed  Google Scholar 

  120. Roberts JA, Cumberland P, Sockett PN, et al. The study of infectious intestinal disease in England: socioeconomic impact. Epidemiol Infect 2003; 130 (1): 1–11

    Article  PubMed  CAS  Google Scholar 

  121. Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003; 97 (6): 1541–1550

    Article  PubMed  Google Scholar 

  122. Barcelo A, Aedo C, Rajpathak S, et al. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003; 81 (1): 19–27

    PubMed  Google Scholar 

  123. Corso PS, Kramer MH, Blair KA, et al. Cost of illness in the 1993 waterborne Cryptosporidium outbreak, Milwaukee, Wisconsin. Emerg Infect Dis 2003; 9 (4): 426–431

    Article  PubMed  Google Scholar 

  124. Dockerty JD, Skegg DC, Williams SM. Economic effects of childhood cancer on families. J Paediatr Child Health 2003; 39 (4): 254–258

    Article  PubMed  CAS  Google Scholar 

  125. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36 (11): 1397–1403

    Article  PubMed  Google Scholar 

  126. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26 (6): 1790–1795

    Article  PubMed  Google Scholar 

  127. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31 (5): 1312–1317

    Article  PubMed  Google Scholar 

  128. Chesson HW, Pinkerton SD, Voigt R, et al. HIV infections and associated costs attributable to syphilis coinfection among African Americans. Am J Public Health 2003; 93 (6): 943–948

    Article  PubMed  Google Scholar 

  129. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111 (6): 1212–1218

    Article  PubMed  Google Scholar 

  130. Daviglus ML, Liu K, Yan LL, et al. Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA 2004; 292 (22): 2743–2749

    Article  PubMed  CAS  Google Scholar 

  131. Wolstenholme J, Fenn P, Gray A, et al. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002; 181: 36–42

    Article  PubMed  CAS  Google Scholar 

  132. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002; 20 (2): 260–267

    Article  PubMed  Google Scholar 

  133. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001; 119 (2): 344–352

    Article  PubMed  CAS  Google Scholar 

  134. Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med 2000; 9 (10): 989–996

    Article  PubMed  CAS  Google Scholar 

  135. Druss BG, Rosenheck RA, Sledge WH. Health and disability costs of depressive illness in a major US corporation. Am J Psychiatry 2000; 157 (8): 1274–1278

    Article  PubMed  CAS  Google Scholar 

  136. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118 (5): 1278–1285

    Article  PubMed  CAS  Google Scholar 

  137. Cavigelli A, Fischer R, Dietz V. Socioeconomic outcome of paraplegia compared to lower limb amputation. Spinal Cord 2002; 40 (4): 174–177

    Article  PubMed  CAS  Google Scholar 

  138. Hedelin H, Holmang S, Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002; 36 (5): 344–347

    Article  PubMed  Google Scholar 

  139. O’Shea E, O’Reilly S. The economic and social cost of dementia in Ireland. Int J Geriatr Psychiatry 2000; 15 (3): 208–218

    Article  PubMed  Google Scholar 

  140. Max W, Rice DP, Sung HY, et al. The economic burden of prostate cancer, California, 1998. Cancer 2002; 94 (11): 2906–2913

    Article  PubMed  Google Scholar 

  141. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46 (6): 850–860

    Article  PubMed  Google Scholar 

  142. Patel A, Knapp M, Henderson J, et al. The economic consequences of social phobia. J Affect Disord 2002; 68 (2–3): 221–233

    Article  PubMed  Google Scholar 

  143. Liu JW, Su YK, Liu CF, et al. Nosocomial blood-stream infection in patients with end-stage renal disease: excess length of hospital stay, extra cost and attributable mortality. J Hosp Infect 2002; 50 (3): 224–227

    Article  PubMed  CAS  Google Scholar 

  144. Wolf A, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6 (2): 97–106

    Article  PubMed  CAS  Google Scholar 

  145. Rein DB, Kassler WJ, Irwin KL, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95 (3): 397–402

    Article  PubMed  CAS  Google Scholar 

  146. Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study: Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy 2000; 51 (1): 1–18

    Article  PubMed  CAS  Google Scholar 

  147. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000; 106 (3): 493–499

    Article  PubMed  CAS  Google Scholar 

  148. Taylor MC, Greig PD, Detsky AS, et al. Factors associated with the high cost of liver transplantation in adults. Can J Surg 2002; 45 (6): 425–434

    PubMed  Google Scholar 

  149. Khetsuriani N, Holman RC, Anderson LJ. Burden of encephalitis-associated hospitalizations in the United States, 1988–1997. Clin Infect Dis 2002; 35 (2): 175–182

    Article  PubMed  Google Scholar 

  150. Scuvee-Moreau J, Kurz X, Dresse A, et al. The economic impact of dementia in Belgium: results of the National Dementia Economic Study (NADES). Acta Neurol Belg 2002; 102 (3): 104–113

    PubMed  CAS  Google Scholar 

  151. Berto P, Degli Esposti E, Ruffo P, et al. The pandora project: cost of hypertension from a general practitioner database. Blood Press 2002; 11 (3): 151–156

    Article  PubMed  Google Scholar 

  152. Amonkar MM, Kalsekar ID, Boyer JG. The economic burden of Barrett’s esophagus in a Medicaid population. Ann Pharmacother 2002; 36 (4): 605–611

    Article  PubMed  Google Scholar 

  153. Babu BV, Nayak AN, Dhal K, et al. The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Trop 2002; 82 (1): 31–38

    Article  PubMed  CAS  Google Scholar 

  154. March L, Cross M, Tribe K, et al. Cost of joint replacement surgery for osteoarthritis: the patients’ perspective. J Rheumatol 2002; 29 (5): 1006–1014

    PubMed  Google Scholar 

  155. Dietrich ES, Demmler M, Schulgen G, et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002; 30 (2): 61–67

    Article  PubMed  CAS  Google Scholar 

  156. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden [published erratum appears in Pharmacoeconomics 2003; 21 (2): 148]. Pharmacoeconomics 2002; 20 (5): 347–355

    Article  PubMed  Google Scholar 

  157. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249 (2): 152–163

    Article  PubMed  Google Scholar 

  158. Liu JL, Maniadakis N, Gray A, et al. The economic burden of coronary heart disease in the UK. Heart 2002; 88 (6): 597–603

    Article  PubMed  CAS  Google Scholar 

  159. Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer’s Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20 (9): 629–637

    Article  PubMed  Google Scholar 

  160. Max W, Sinnot P, Kao C, et al. The burden of osteoporosis in California, 1998. Osteoporos Int 2002; 13 (6): 493–500

    Article  PubMed  CAS  Google Scholar 

  161. Cooper NJ, Mugford M, Symmons DP, et al. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology 2002; 41 (7): 767–774

    Article  PubMed  CAS  Google Scholar 

  162. Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002; 59 (11): 1721–1729

    Article  PubMed  CAS  Google Scholar 

  163. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002; 42 (6): 501–509

    Article  PubMed  Google Scholar 

  164. Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (MediCal) program. J Affect Disord 2002; 71 (1-3): 131–139

    Article  PubMed  Google Scholar 

  165. McGarry LJ, Thompson D, Millham FH, et al. Outcomes and costs of acute treatment of traumatic brain injury. J Trauma 2002; 53 (6): 1152–1159

    Article  PubMed  Google Scholar 

  166. Andersson A, Levin LA, Oberg B, et al. Health care and social welfare costs in home-based and hospital-based rehabilitation after stroke. Scand J Caring Sci 2002; 16 (4): 386–392

    Article  PubMed  Google Scholar 

  167. Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999; 159 (18): 2177–2183

    Article  PubMed  CAS  Google Scholar 

  168. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999; 22 Suppl. 2: S386–S393

    PubMed  Google Scholar 

  169. Blomqvist P, Lycke J, Strang P, et al. Brain tumours in Sweden 1996: care and costs. J Neurol Neurosurg Psychiatry 2000; 69 (6): 792–798

    Article  PubMed  CAS  Google Scholar 

  170. Hirshberg J, Rees RS, Marchant B, et al. Osteomyelitis related to pressure ulcers: the cost of neglect. Adv Skin Wound Care 2000; 13 (1): 25–29

    PubMed  CAS  Google Scholar 

  171. Baldwin ZK, Meyerson SL, Skelly CL, et al. Estimating the contemporary in-hospital costs of carotid endarterectomy. Ann Vasc Surg 2000; 14 (3): 210–215

    Article  PubMed  CAS  Google Scholar 

  172. Newhall-Perry K, Law NJ, Ramos B, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis: Western Consortium of Practicing Rheumatologists. J Rheumatol 2000; 27 (5): 1156–1163

    PubMed  CAS  Google Scholar 

  173. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41 (3): 342–351

    Article  PubMed  CAS  Google Scholar 

  174. Yang MC, Huang IC. Establishing a cost estimation model for hypertension and its related diseases in Taiwan. J Formos Med Assoc 1999; 98 (6): 394–402

    PubMed  CAS  Google Scholar 

  175. Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197–208

    Article  PubMed  CAS  Google Scholar 

  176. Ehrnborg C, Hakkaart-Van Roijen L, Jonsson B, et al. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000; 17 (6): 621–628

    Article  PubMed  CAS  Google Scholar 

  177. Tan HL. Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. Pharmacoeconomics 2000; 17 (1): 77–107

    Article  PubMed  CAS  Google Scholar 

  178. Mauskopf JA, David K, Grainger DL, et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 1999; 60 Suppl. 19: 14–19

    PubMed  Google Scholar 

  179. Anis AH, Guh D, Stieb D, et al. The costs of cardiorespiratory disease episodes in a study of emergency department use. Can J Public Health 2000; 91 (2): 103–106

    PubMed  CAS  Google Scholar 

  180. Kernick DP, Reinhold DM, Netten A. What does it cost the patient to see the doctor? Br J Gen Pract 2000; 50 (454): 401–403

    PubMed  CAS  Google Scholar 

  181. Polednak AP. Hospital charges for colorectal cancer patients first admitted through an emergency department. J Health Care Finance 2000; 27 (1): 44–49

    PubMed  CAS  Google Scholar 

  182. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90 (10): 1562–1569

    Article  PubMed  CAS  Google Scholar 

  183. Levy P, Levy E, Audran M, et al. The cost of osteoporosis in men: the French situation. Bone 2002; 30 (4): 631–636

    Article  PubMed  CAS  Google Scholar 

  184. Jacobs P, Blanchard JF, James RC, et al. Excess costs of diabetes in the Aboriginal population of Manitoba, Canada. Can J Public Health 2000; 91 (4): 298–301

    PubMed  CAS  Google Scholar 

  185. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35 (3): 229–231

    Article  PubMed  CAS  Google Scholar 

  186. Wildhagen MF, Verheij JB, Verzijl JG, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1 [published erratum appears in Thorax 1997 Feb; 52 (2): 204. Note: Habbema F corrected to Habbema JD]. Thorax 1996; 51 (3): 298–301

    Article  PubMed  CAS  Google Scholar 

  187. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998; 51 (3): 355–361

    Article  PubMed  CAS  Google Scholar 

  188. Ramaiah KD, Ramu K, Guyatt H, et al. Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Trop Med Int Health 1998; 3 (2): 108–115

    Article  PubMed  CAS  Google Scholar 

  189. Rouillon F, Toumi M, Dansette GY, et al. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997; 11 (6): 578–594

    Article  PubMed  CAS  Google Scholar 

  190. Montron A, Guignard E, Pelc A, et al. Peripheral arterial obliterative disease: cost of illness in France. Pharmacoeconomics 1998; 13 (1 Pt 1): 51–59

    Article  PubMed  CAS  Google Scholar 

  191. Hakkaart-van Roijen L, Beckers A, Stevenaert A, et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998; 14 (4): 395–403

    Article  Google Scholar 

  192. Reginster JY, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999; 15 (5): 507–514

    Article  PubMed  CAS  Google Scholar 

  193. Guest JF, Cookson RF. Cost of schizophrenia to UK Society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15 (6): 597–610

    Article  PubMed  CAS  Google Scholar 

  194. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 1999; 16 (1): 59–69

    Article  PubMed  CAS  Google Scholar 

  195. Plumb JM, Guest JF. Annual cost of erectile dysfunction to UK Society. Pharmacoeconomics 1999; 16 (6): 699–709

    Article  PubMed  CAS  Google Scholar 

  196. Lane A. Direct costs of osteoporosis for New Zealand women. Pharmacoeconomics 1996; 9 (3): 231–245

    Article  PubMed  CAS  Google Scholar 

  197. Petrou S, Dooley M, Whitaker L, et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. Pharmacoeconomics 1996; 9 (4): 332–340

    Article  PubMed  CAS  Google Scholar 

  198. Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States [published erratum appears in Clin Ther 1999 Feb; 21 (2): 430]. Clin Ther 1998; 20 (5): 993–1008

    Article  PubMed  CAS  Google Scholar 

  199. Devlin NJ, Scuffham PA, Bunt LJ. The social costs of alcohol abuse in New Zealand. Addiction 1997; 92 (11): 1491–1505

    Article  PubMed  CAS  Google Scholar 

  200. Muller C, Fahs MC, Mulak G, et al. Pediatric AIDS at Mount Sinai Medical Center 1988-89: a study of costs and social severity. Soc Work Health Care 1996; 22 (4): 1–20

    Article  PubMed  CAS  Google Scholar 

  201. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159 (8): 813–818

    Article  PubMed  CAS  Google Scholar 

  202. Single E, Robson L, Xie X, et al. The economic costs of alcohol, tobacco and illicit drugs in Canada, 1992. Addiction 1998; 93 (7): 991–1006

    Article  PubMed  CAS  Google Scholar 

  203. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997; 19 (6): 1470–1495

    Article  PubMed  CAS  Google Scholar 

  204. Ray NF, Denton WG, Thamer M, et al. Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994. J Am Coll Surg 1998; 186 (1): 1–9

    Article  PubMed  CAS  Google Scholar 

  205. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998; 81 (9): 1110–1115

    Article  PubMed  CAS  Google Scholar 

  206. Metcalf M, Brown N, Peterson S, et al. Health care costs associated with chronic hepatitis B. Am J Health Syst Pharm 1999; 56 (3): 232–236

    PubMed  CAS  Google Scholar 

  207. MacKinnon NJ, Flagstad MS, Peterson CR, et al. Disease management program for asthma: baseline assessment of resource use. Am J Health Syst Pharm 1996; 53 (5): 535–541

    PubMed  CAS  Google Scholar 

  208. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35 (8): 781–790

    Article  PubMed  CAS  Google Scholar 

  209. Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996; 87 (3): 321–327

    Article  PubMed  CAS  Google Scholar 

  210. Sauerborn R, Nougtara A, Hien M, et al. Seasonal variations of household costs of illness in Burkina Faso. Soc Sci Med 1996; 43 (3): 281–290

    Article  PubMed  CAS  Google Scholar 

  211. Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24 (6): 1051–1060

    PubMed  CAS  Google Scholar 

  212. Konradsen F, van der Hoek W, Amerasinghe PH, et al. Household responses to malaria and their costs: a study from rural Sri Lanka. Trans R Soc Trop Med Hyg 1997; 91 (2): 127–130

    Article  PubMed  CAS  Google Scholar 

  213. Buzby JC, Roberts T. Economic costs and trade impacts of microbial foodborne illness. World Health Stat Q 1997; 50 (12): 57–66

    PubMed  CAS  Google Scholar 

  214. Asenso-Okyere WK, Dzator JA. Household cost of seeking malaria care: a retrospective study of two districts in Ghana. Soc Sci Med 1997; 45 (5): 659–667

    Article  PubMed  CAS  Google Scholar 

  215. Woo J, Ho SC, Chan SG, et al. An estimate of chronic disease burden and some economic consequences among the elderly Hong Kong population. J Epidemiol Community Health 1997; 51 (5): 486–489

    Article  PubMed  CAS  Google Scholar 

  216. Sagmeister M, Gessner U, Oggier W, et al. An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997; 18 (7): 1102–1109

    Article  PubMed  CAS  Google Scholar 

  217. Swinburn B, Ashton T, Gillespie J, et al. Health care costs of obesity in New Zealand. Int J Obes Relat Metab Disord 1997; 21 (10): 891–896

    Article  PubMed  CAS  Google Scholar 

  218. Callender TJ, Ristovv M, Guerra M, et al. Social and economic impact of neurotoxicity in hazardous waste workers in Lenoir, North Carolina. Environ Res 1997; 73 (1-2): 166–174

    Article  PubMed  CAS  Google Scholar 

  219. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156 (3 Pt 1): 787–793

    PubMed  CAS  Google Scholar 

  220. Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-associated Guillain-Barre syndrome. J Infect Dis 1997; 176 Suppl. 2: S192–S197

    Article  PubMed  Google Scholar 

  221. Healey A, Knapp M, Astin J, et al. Economic burden of drug dependency: social costs incurred by drug users at intake to the National Treatment Outcome Research Study. Br J Psychiatry 1998; 173: 160–165

    Article  PubMed  CAS  Google Scholar 

  222. Clark KL, Howell RM, Scott RM, et al. The socioeconomic impact of hepatitis E in Nepal. Am J Trop Med Hyg 1999; 61 (3): 505–510

    PubMed  CAS  Google Scholar 

  223. Evers SM, Engel GL, Ament AJ. Cost of stroke in The Netherlands from a societal perspective. Stroke 1997; 28 (7): 1375–1381

    Article  PubMed  CAS  Google Scholar 

  224. Warner DC, McCandless RR, De Nino LA, et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996; 19 (12): 1416–1419

    Article  PubMed  CAS  Google Scholar 

  225. Chesson HW, Pinkerton SD, Irwin KL, et al. New HIV cases attributable to syphilis in the USA: estimates from a simplified transmission model. AIDS 1999; 13 (11): 1387–1396

    Article  PubMed  CAS  Google Scholar 

  226. Meerding WJ, Bonneux L, Polder JJ, et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 1998; 317 (7151): 111–115

    Article  PubMed  CAS  Google Scholar 

  227. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76 (2): 159–162

    Article  PubMed  CAS  Google Scholar 

  228. Goeree R, O’Brien BJ, Goering P, et al. The economic burden of schizophrenia in Canada. Can J Psychiatry 1999; 44 (5): 464–472

    PubMed  CAS  Google Scholar 

  229. Chew FT, Goh DY, Lee BW. The economic cost of asthma in Singapore. Aust N Z J Med 1999; 29 (2): 228–233

    Article  PubMed  CAS  Google Scholar 

  230. Pichichero ME, Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med 1997; 151 (1): 35–40

    Article  PubMed  CAS  Google Scholar 

  231. Kurz X, Broers M, Scuvee-Moreau J, et al. Methodological issues in a cost-of-dementia study in Belgium: the NAtional Dementia Economic Study (NADES). Acta Neurol Belg 1999; 99 (3): 167–175

    PubMed  CAS  Google Scholar 

  232. Patience D, Buxton M, Chick J, et al. The SECCAT Survey: II. The Alcohol Related Problems Questionnaire as a proxy for resource costs and quality of life in alcoholism treatment. Study of Socio-Economic Consequences and Costs of Alcoholism and Treatment. Alcohol Alcohol 1997; 32 (1): 79–84

    Article  PubMed  CAS  Google Scholar 

  233. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997; 45 (3): 281–287

    PubMed  CAS  Google Scholar 

  234. De Graeve D, Lescrauwaet B, Nonneman W. Patient classification and cost analysis of AIDS and HIV: the case of Belgium [published erratum appears in Health Policy 1997 Jun; 40 (3): 265]. Health Policy 1997; 39 (2): 93–106

    Article  PubMed  Google Scholar 

  235. Zethraeus N, Molin T, Henriksson P, et al. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246 (2): 151–159

    Article  PubMed  CAS  Google Scholar 

  236. Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998; 244 (6): 461–468

    Article  PubMed  CAS  Google Scholar 

  237. Kiiskinen U, Vartiainen E, Puska P, et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998; 16 (8): 1103–1112

    Article  PubMed  CAS  Google Scholar 

  238. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1 Pt 1): 22–27

    PubMed  CAS  Google Scholar 

  239. Lozano P, Sullivan SD, Smith DH, et al. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol 1999; 104 (5): 957–963

    Article  PubMed  CAS  Google Scholar 

  240. Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med 1999; 29 (3): 173–186

    Article  PubMed  CAS  Google Scholar 

  241. Miller VL, Rice JC, DeVoe M, et al. An analysis of program and family costs of case managed care for technology-dependent infants with bronchopulmonary dysplasia. J Pediatr Nurs 1998; 13 (4): 244–251

    Article  PubMed  CAS  Google Scholar 

  242. Rutten-van Molken MP, Postma MJ, Joore MA, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999; 93 (11): 779–787

    Article  Google Scholar 

  243. Fornaro P, Gandini F, Marin M, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Italian Sentinel Group on Pediatric Infectious Diseases. Pediatr Infect Dis J 1999; 18 (5): 414–419

    Article  PubMed  CAS  Google Scholar 

  244. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT). Pediatrics 1999; 104 (1 Pt 1): 7–14

    Article  PubMed  CAS  Google Scholar 

  245. Bowie RD, Tobias MI, Williams T. The private costs of HIV/AIDS. N Z Med J 1996; 109 (1016): 51–54

    PubMed  CAS  Google Scholar 

  246. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol 1996; 49 (1): 95–103

    Article  PubMed  CAS  Google Scholar 

  247. Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 2000; 19 (2): 87–99

    Article  PubMed  CAS  Google Scholar 

  248. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997; 349 (9052): 604–608

    Article  PubMed  CAS  Google Scholar 

  249. Zmirou D, Deloraine A, Balducci F, et al. Health effects costs of particulate air pollution. J Occup Environ Med 1999; 41 (10): 847–856

    Article  PubMed  CAS  Google Scholar 

  250. Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999; 13 (2): 281–286

    Article  PubMed  CAS  Google Scholar 

  251. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12 (6): 1322–1326

    Article  PubMed  CAS  Google Scholar 

  252. Kiiskinen U, Vartiainen E, Pekurinen M, et al. Does prevention of cardiovascular diseases lead to decreased cost of illness? Twenty years of experience from Finland. Prev Med 1997; 26 (2): 220–226

    Article  PubMed  CAS  Google Scholar 

  253. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98 (3): 398–406

    Article  PubMed  CAS  Google Scholar 

  254. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 401–407

    Article  PubMed  CAS  Google Scholar 

  255. Ray NF, Baraniuk JN, Thamer M, et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 408–414

    Article  PubMed  CAS  Google Scholar 

  256. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27 (4): 781–788

    Article  PubMed  CAS  Google Scholar 

  257. Torgerson PR, Dowling PM. Estimating the economic effects of cystic echinococcosis. Part 2: an endemic region in the United Kingdom, a wealthy, industrialized economy. Ann Trop Med Parasitol 2001; 95 (2): 177–185

    Article  PubMed  CAS  Google Scholar 

  258. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002; 46 (1): 223–231

    Article  PubMed  Google Scholar 

  259. Ungar WJ, Coyte PC, Pharmacy Medication Monitoring Program Advisory B. Prospective study of the patient-level cost of asthma care in children. Pediatr Pulmonol 2001; 32 (2): 101–108

    Article  PubMed  CAS  Google Scholar 

  260. Yelin E, Herrndorf A, Trupin L, et al. A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care. Arthritis Rheum 2001; 44 (5): 1160–1169

    Article  PubMed  CAS  Google Scholar 

  261. Santos R, Cifaldi M, Gregory C, et al. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Manag Care 1999; 5 (4 Suppl.): S225–S234

    PubMed  CAS  Google Scholar 

  262. Tollestrup K, Frost FJ, Stidley CA, et al. The excess costs of breast cancer health care in Hispanic and non-Hispanic female members of a managed care organization. Breast Cancer Res Treat 2001; 66 (1): 25–31

    Article  PubMed  CAS  Google Scholar 

  263. Lapins DL, Urdaneta ME, Barrett J, et al. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000; 6 (9): 973–981

    PubMed  CAS  Google Scholar 

  264. Soni A, Sonnenberg A. Healthcare resource utilization in the management of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2001; 15 (7): 945–951

    Article  PubMed  CAS  Google Scholar 

  265. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, et al. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998; 37 (8): 837–847

    Article  PubMed  Google Scholar 

  266. Sutcliffe N, Clarke AE, Taylor R, et al. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology 2001; 40 (1): 37–47

    Article  PubMed  CAS  Google Scholar 

  267. Mark TL, Woody GE, Juday T, et al. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61 (2): 195–206

    Article  PubMed  CAS  Google Scholar 

  268. Zimmerman CM, Bresee JS, Parashar UD, et al. Cost of diarrhea-associated hospitalizations and outpatient visits in an insured population of young children in the United States. Pediatr Infect Dis J 2001; 20 (1): 14–19

    Article  PubMed  CAS  Google Scholar 

  269. Lyu RR, McCombs JS, Johnstone BM, et al. Use of conventional antipsychotics and the cost of treating schizophrenia. Health Care Financ Rev 2001; 23 (2): 83–99

    PubMed  CAS  Google Scholar 

  270. McNamee P, Bond J, Buck D, et al. Costs of dementia in England and Wales in the 21st century. Br J Psychiatry 2001; 179: 261–266

    Article  PubMed  CAS  Google Scholar 

  271. Chan AT, Jacobs P, Yeo W, et al. The cost of palliative care for hepatocellular carcinoma in Hong Kong. Pharmacoeconomics 2001; 19 (9): 947–953

    Article  PubMed  CAS  Google Scholar 

  272. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96 (11): 3122–3129

    Article  PubMed  CAS  Google Scholar 

  273. van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001; 37 (17): 2204–2211

    Article  PubMed  Google Scholar 

  274. Szucs TD, Berger K, Fisman DN, et al. The estimated economic burden of genital herpes in the United States: an analysis using two costing approaches. BMC Infect Dis 2001; 1: 5

    Article  PubMed  CAS  Google Scholar 

  275. Thomas SV, Sarma PS, Alexander M, et al. Economic burden of epilepsy in India. Epilepsia 2001; 42 (8): 1052–1060

    Article  PubMed  CAS  Google Scholar 

  276. Decock RC, Depoorter AM, De Graeve D, et al. Direct costs of health care for HIV/AIDS patients in Belgium. AIDS Care 2001; 13 (6): 721–731

    Article  PubMed  CAS  Google Scholar 

  277. Birnbaum HG, Morley M, Greenberg PE, et al. Economic burden of pneumonia in an employed population. Arch Intern Med 2001; 161 (22): 2725–2731

    Article  PubMed  CAS  Google Scholar 

  278. Morgan CL, Kerr MP. Estimated cost of inpatient admissions and outpatient appointments for a population with epilepsy: a record linkage study. Epilepsia 2004; 45 (7): 849–854

    Article  PubMed  Google Scholar 

  279. Dranitsaris G, Maroun J, Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 2005; 13 (5): 318–324

    Article  PubMed  Google Scholar 

  280. Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand 2004; 110 (5): 383–392

    Article  Google Scholar 

  281. Bownds L, Lindekugel R, Stepak P. Economic impact of a hepatitis A epidemic in a midsized urban community: the case of Spokane, Washington. J Community Health 2003; 28 (4): 233–246

    Article  PubMed  Google Scholar 

  282. Khetsuriani N, Quiroz ES, Holman RC, et al. Viral meningitis-associated hospitalizations in the United States, 1988–1999. Neuroepidemiology 2003; 22 (6): 345–352

    Article  PubMed  Google Scholar 

  283. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S43–S50

    Google Scholar 

  284. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S61–S69

    Article  PubMed  Google Scholar 

  285. Beghi E, Garattini L, Ricci E, et al. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004; 45 (2): 171–178

    Article  PubMed  Google Scholar 

  286. Utz JT, Apperson CS, MacCormack JN, et al. Economic and social impacts of La Crosse encephalitis in western North Carolina. Am J Trop Med Hyg 2003; 69 (5): 509–518

    PubMed  Google Scholar 

  287. Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–2363

    Article  PubMed  CAS  Google Scholar 

  288. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood) 2003; Suppl Web Exclusives: W3-219-26

    Google Scholar 

  289. de Zelicourt M, Dardennes R, Verdoux H, et al. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. Pharmacoeconomics 2003; 21 (15): 1081–1090

    Article  PubMed  Google Scholar 

  290. Lodha R, Puranik M, Kattal N, et al. Social and economic impact of childhood asthma. Indian Pediatr 2003; 40 (9): 874–879

    PubMed  Google Scholar 

  291. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6 (1): 59–74

    Article  PubMed  Google Scholar 

  292. Weinmann S, Kamtsiuris P, Henke KD, et al. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol 2003; 14 (1): 18–26

    Article  PubMed  Google Scholar 

  293. McCrone P, Darbishire L, Ridsdale L, et al. The economic cost of chronic fatigue and chronic fatigue syndrome in UK primary care. Psychol Med 2003; 33 (2): 253–261

    Article  PubMed  CAS  Google Scholar 

  294. Le Pen C, Ruszniewski P, Gaudin AF, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 2004; 39 (4): 336–343

    Article  PubMed  Google Scholar 

  295. Johnson RL, Brooks CA, Whiteneck GG. Cost of traumatic spinal cord injury in a population-based registry. Spinal Cord 1996; 34 (8): 470–480

    Article  PubMed  CAS  Google Scholar 

  296. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry Suppl 1998; (34): 4–9

    PubMed  Google Scholar 

  297. Guo JJ, Gibson JT, Gropper DM, et al. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. Am J Manag Care 1998; 4 (10): 1433–1446

    PubMed  CAS  Google Scholar 

  298. Garattini L, Tediosi F, Chiaffarino F, et al. The outpatient cost of diabetes care in Italian diabetes centers. Value Health 2001; 4 (3): 251–257

    Article  PubMed  CAS  Google Scholar 

  299. White AG, Birnbaum HG, Mareva MN, et al. Economic burden of illness for employees with painful conditions. J Occup Environ Med 2005; 47 (9): 884–892

    Article  PubMed  Google Scholar 

  300. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147 (1): 121–126

    Article  PubMed  Google Scholar 

  301. Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment: United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53 (3): 57–59

    Google Scholar 

  302. Schmid A, Burchard H, Clouth J, et al. Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 2002; 3: 377–382

    Article  Google Scholar 

  303. Dodel R, Peter H, Walbert T, et al. The socioeconomic impact of narcolepsy. Sleep 2004; 27 (6): 1123–1128

    PubMed  Google Scholar 

  304. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005; 21 (2): 195–206

    Article  PubMed  Google Scholar 

  305. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48 (7): 515–524

    PubMed  Google Scholar 

  306. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004; 11 (1): 17–33

    Article  PubMed  Google Scholar 

  307. Maumbe BM, Swinton SM. Hidden health costs of pesticide use in Zimbabwe’s smallholder cotton growers. Soc Sci Med 2003; 57 (9): 1559–1571

    Article  PubMed  Google Scholar 

  308. Fendrick AM, Monto AS, Nightengale B, et al. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003; 163 (4): 487–494

    Article  PubMed  Google Scholar 

  309. Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163 (8): 929–935

    Article  PubMed  Google Scholar 

  310. Stevens CA, Turner D, Kuehni CE, et al. The economic impact of preschool asthma and wheeze. Eur Respir J 2003; 21 (6): 1000–1006

    Article  PubMed  CAS  Google Scholar 

  311. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002; 180: 227–233

    Article  Google Scholar 

  312. Polder JJ, Meerding WJ, Bonneux L, et al. Healthcare costs of intellectual disability in the Netherlands: a cost-of-illness perspective. J Intell Disabil Res 2002; 46 (Pt 2): 168–178

    Article  CAS  Google Scholar 

  313. Beutels P, Van Damme P, Van Casteren V, et al. The difficult quest for data on ‘vanishing’ vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 2002; 20 (29-30): 3551–3559

    Article  PubMed  Google Scholar 

  314. Stenevi U, Lundstrom M, Thorburn W. The cost of cataract patients awaiting surgery. Acta Ophthalmol Scand 2000; 78 (6): 703–705

    Article  PubMed  CAS  Google Scholar 

  315. Attanayake N, Fox-Rushby J, Mills A. Household costs of ‘malaria’ morbidity: a study in Matale district, Sri Lanka. Trop Med Int Health 2000; 5 (9): 595–606

    Article  PubMed  CAS  Google Scholar 

  316. Detournay B, Fagnani F, Phillippo M, et al. Obesity morbidity and health care costs in France: an analysis of the 1991–1992 Medical Care Household Survey. Int J Obes Relat Metab Disord 2000; 24 (2): 151–155

    Article  PubMed  CAS  Google Scholar 

  317. Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol 1996; 135 (1): 20–23

    Article  PubMed  CAS  Google Scholar 

  318. Simmons D, Peng A, Cecil A, et al. The personal costs of diabetes: a significant barrier to care in South Auckland. N Z Med J 1999; 112 (1097): 383–385

    PubMed  CAS  Google Scholar 

  319. Withington SG, Chambers ST. The cost of campylobacteriosis in New Zealand in 1995. N Z Med J 1997; 110 (1046): 222–224

    PubMed  CAS  Google Scholar 

  320. Suleiman TG, Ohaeri JU, Lawal RA, et al. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997; 171: 364–368

    Article  PubMed  CAS  Google Scholar 

  321. Wimo A, Karlsson G, Sandman PO, et al. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997; 12 (8): 857–861

    Article  PubMed  CAS  Google Scholar 

  322. Dowell CJ, Bryant CM, Moore KH, et al. Calculating the direct costs of urinary incontinence: a new test instrument. BJU Int 1999; 83 (6): 596–606

    Article  PubMed  CAS  Google Scholar 

  323. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. Pediatrics 1999; 104 (1 Pt 1): 1–6

    Article  PubMed  CAS  Google Scholar 

  324. Carabin H, Gyorkos TW, Soto JC, et al. Estimation of direct and indirect costs because of common infections in toddlers attending day care centers. Pediatrics 1999; 103 (3): 556–564

    Article  PubMed  CAS  Google Scholar 

  325. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63 (3): 461–465

    Article  PubMed  Google Scholar 

  326. Nguyen PM, Kenny DJ, Barrett EJ. Socio-economic burden of permanent incisor replantation on children and parents. Dent Traumatol 2004; 20 (3): 123–133

    Article  PubMed  Google Scholar 

  327. Wang G, Helmick CG, Macera C, et al. Inactivity-associated medical costs among US adults with arthritis. Arthritis Rheumat 2001; 45 (5): 439–445

    Article  PubMed  CAS  Google Scholar 

  328. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001; 144 (3): 514–522

    Article  PubMed  CAS  Google Scholar 

  329. Janssen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 2004; 52 (1): 80–85

    Article  PubMed  Google Scholar 

  330. Babu BV, Nayak AN. Treatment costs and work time loss due to episodic adenolymphangitis in lymphatic filariasis patients in rural communities of Orissa, India. Trop Med Int Health 2003; 8 (12): 1102–1109

    Article  PubMed  CAS  Google Scholar 

  331. Alberini A, Krupnick A. Cost-of-illness and willingness-to-pay estimates of the benefits of improved air quality: evidence from Taiwan. Land Econ 2000; 76 (1): 37–53

    Article  Google Scholar 

  332. Hamelsky SW, Lipton RB, Stewart WF. An assessment of the burden of migraine using the willingness to pay model. Cephalalgia 2005; 25 (2): 87–100

    Article  PubMed  CAS  Google Scholar 

  333. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 173 (4): 1309–1313

    Article  PubMed  Google Scholar 

  334. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36 (1): 11–19

    Article  PubMed  Google Scholar 

  335. Lapsley HM, March LM, Tribe KL, et al. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002; 61 (9): 818–821

    Article  PubMed  CAS  Google Scholar 

  336. Rendu A, Moran P, Patel A, et al. Economic impact of personality disorders in UK primary care attenders. Br J Psychiatry 2002; 181: 62–66

    Article  PubMed  Google Scholar 

  337. Rockwood K. Vascular cognitive impairment and vascular dementia. J Neurol Sci 2002; 203-204: 23–27

    Article  PubMed  Google Scholar 

  338. Hussey LC, Hardin S, Blanchette C. Outpatient costs of medications for patients with chronic heart failure. Am J Crit Care 2002; 11 (5): 474–478

    PubMed  Google Scholar 

  339. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162 (18): 2061–2069

    Article  PubMed  Google Scholar 

  340. Severens JL, Habraken JM, Duivenvoorden S, et al. The cost of illness of pressure ulcers in The Netherlands. Adv Skin Wound Care 2002; 15 (2): 72–77

    Article  PubMed  Google Scholar 

  341. Fillit H, Hill J. The costs of vascular dementia: a comparison with Alzheimer’s disease. J Neurol Sci 2002; 203-204: 35–39

    Article  PubMed  Google Scholar 

  342. Birnbaum HG, Berger WE, Greenberg PE, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol 2002; 109 (2): 264–270

    Article  PubMed  Google Scholar 

  343. Krappweis J, Rentsch A, Schwarz UI, et al. Outpatient costs of osteoporosis in a national health insurance population. Clin Ther 1999; 21 (11): 2001–2014

    Article  PubMed  CAS  Google Scholar 

  344. Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37 (4): 564–569

    Article  PubMed  CAS  Google Scholar 

  345. Hux MJ, O’Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer’s disease and costs of caring. CMAJ 1998; 159 (5): 457–465

    PubMed  CAS  Google Scholar 

  346. Patricoski CT, Steiner G. Cost of medications for patients with ischemic heart disease in a rural family practice center. J Am Board Fam Pract 1999; 12 (3): 200–205

    PubMed  CAS  Google Scholar 

  347. Petruzzelli GJ, Brockenbrough JM, Vandevender D, et al. The influence of reconstructive modality on cost of care in head and neck oncologic surgery. Arch Otolaryngol Head Neck Surg 2002; 128 (12): 1377–1380

    PubMed  Google Scholar 

  348. Dewey HM, Thrift AG, Mihalopoulos C, et al. Informal care for stroke survivors: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2002; 33 (4): 1028–1033

    Article  PubMed  CAS  Google Scholar 

  349. Kirchner V, Elloy MD, Silver LE, et al. Dementia: the cost of care for behaviourally disturbed patients living in the community. Int J Geriatr Psychiatry 2000; 15 (11): 1000–1004

    Article  PubMed  CAS  Google Scholar 

  350. Sundberg G, Bagust A, Terent A. A model for costs of stroke services. Health Policy 2003; 63 (1): 81–94

    Article  PubMed  Google Scholar 

  351. Shih YC, Hartzema AG, Tolleson-Rinehart S. Labor costs associated with incontinence in long-term care facilities. Urology 2003; 62 (3): 442–446

    Article  PubMed  Google Scholar 

  352. Bernal P, Estroff DB, Aboudarham JF, et al. Psychosocial morbidity: the economic burden in a pediatric health maintenance organization sample. Arch Pediatr Adolesc Med 2000; 154 (3): 261–266

    PubMed  CAS  Google Scholar 

  353. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98 (5): 1064–1072

    PubMed  Google Scholar 

  354. Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003; 98 (4): 844–849

    Article  PubMed  Google Scholar 

  355. Merkesdal S, Ruof J, Huelsemann JL, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005; 53 (2): 234–240

    Article  PubMed  Google Scholar 

  356. Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med 2005; 47 (5): 439–446

    Article  PubMed  Google Scholar 

  357. Vijan S, Hayward RA, Langa KM. The impact of diabetes on workforce participation: results from a national household sample. Health Serv Res 2004; 39 (6 Pt 1): 1653–1669

    Article  PubMed  Google Scholar 

  358. Rosen S, Vincent JR, MacLeod W, et al. The cost of HIV/AIDS to businesses in southern Africa. AIDS 2004; 18 (2): 317–324

    Article  PubMed  Google Scholar 

  359. Oliva J, Roa C, del Llano J. Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study. Pharmacoeconomics 2003; 21 (15): 1113–11121

    Article  PubMed  Google Scholar 

  360. Frick KD, Basilion EV, Hanson CL, et al. Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol 2003; 10 (2): 121–132

    Article  PubMed  Google Scholar 

  361. Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 2003; 135 (4): 471–476

    Article  PubMed  Google Scholar 

  362. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290 (18): 2443–2454

    Article  PubMed  CAS  Google Scholar 

  363. Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression [published erratum appears in JAMA 2003 Oct 22; 290 (16): 2218]. JAMA 2003; 289 (23): 3135–3144

    Article  PubMed  Google Scholar 

  364. Boden LI, Galizzi M. Economic consequences of workplace injuries and illnesses: lost earnings and benefit adequacy. Am J Ind Med 1999; 36 (5): 487–503

    Article  PubMed  CAS  Google Scholar 

  365. Onwujekwe O, Chima R, Okonkwo P. Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holoendemic Nigerian communities. Health Policy 2000; 54 (2): 143–159

    Article  PubMed  CAS  Google Scholar 

  366. Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61 (5): 429–437

    Article  PubMed  CAS  Google Scholar 

  367. Ward MM, Javitz HS, Smith WM, et al. Lost income and work limitations in persons with chronic respiratory disorders. J Clin Epidemiol 2002; 55 (3): 260–268

    Article  PubMed  Google Scholar 

  368. de Loes M, Jansson B. Work-related acute injuries from mandatory fitness training in the Swedish Police Force. Int J Sports Med 2002; 23 (3): 212–217

    Article  PubMed  Google Scholar 

  369. Bramley TJ, Lerner D, Sames M. Productivity losses related to the common cold. J Occup Environ Med 2002; 44 (9): 822–829

    Article  PubMed  Google Scholar 

  370. Yassin AS, Beckles GL, Messonnier ML. Disability and its economic impact among adults with diabetes. J Occup Environ Med 2002; 44 (2): 136–142

    Article  PubMed  Google Scholar 

  371. Pop PH, Gierveld CM, Karis HA, et al. Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eur J Neurol 2002; 9 (2): 171–174

    Article  PubMed  CAS  Google Scholar 

  372. Myles S, Douglas MJ, Ward HJ, et al. Variant Creutzfeldt-Jakob disease: costs borne by families. Health Soc Care Community 2002; 10 (2): 91–98

    Article  PubMed  Google Scholar 

  373. Valdmanis V, Smith DW, Page MR. Productivity and economic burden associated with diabetes. Am J Public Health 2001; 91 (1): 129–130

    Article  PubMed  CAS  Google Scholar 

  374. Ruben RJ. Redefining the survival of the fittest: communication disorders in the 21st century. Laryngoscope 2000; 110 (2 Pt 1): 241–245

    Article  PubMed  CAS  Google Scholar 

  375. Herrin J, Cangialose CB, Boccuzzi SJ, et al. Household income losses associated with ischaemic heart disease for US employees. Pharmacoeconomics 2000; 17 (3): 305–314

    Article  PubMed  CAS  Google Scholar 

  376. Konradsen F, van der Hoek W, Amerasinghe PH, et al. Measuring the economic cost of malaria to households in Sri Lanka. Am J Trop Med Hyg 1997; 56 (6): 656–660

    PubMed  CAS  Google Scholar 

  377. Anand K, Pandav CS, Nath LM. Impact of HIV/AIDS on the national economy of India. Health Policy 1999; 47 (3): 195–205

    Article  PubMed  CAS  Google Scholar 

  378. Hutubessy RC, van Tulder MW, Vondeling H, et al. Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method. Pain 1999; 80 (1-2): 201–207

    Article  PubMed  CAS  Google Scholar 

  379. Guico-Pabia CJ, Murray JF, Teutsch SM, et al. Indirect cost of ischemic heart disease to employers. Am J Manag Care 2001; 7 (1): 27–34

    PubMed  CAS  Google Scholar 

  380. Crystal-Peters J, Crown WH, Goetzel RZ, et al. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000; 6 (3): 373–378

    PubMed  CAS  Google Scholar 

  381. Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000; 22 (11): 1333–1345

    Article  PubMed  CAS  Google Scholar 

  382. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16 (11): 770–778

    Article  PubMed  CAS  Google Scholar 

  383. Grassly NC, Desai K, Pegurri E, et al. The economic impact of HIV/AIDS on the education sector in Zambia. AIDS 2003; 17 (7): 1039–1044

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Akobundu acknowledges the financial support of the Pharmaceutical Research and Manufacturers of America Foundation through its Post-Doctoral Fellowship in Health Outcomes. The authors have no relevant conflicts of interest to declare. All the authors made substantial contributions to the intellectual content of the article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ebere Akobundu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akobundu, E., Ju, J., Blatt, L. et al. Cost-of-Illness Studies. Pharmacoeconomics 24, 869–890 (2006). https://doi.org/10.2165/00019053-200624090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624090-00005

Keywords

Navigation